MX2015012274A - Agentes de sub-regulacion del receptor de androgeno y uso de los mismos. - Google Patents

Agentes de sub-regulacion del receptor de androgeno y uso de los mismos.

Info

Publication number
MX2015012274A
MX2015012274A MX2015012274A MX2015012274A MX2015012274A MX 2015012274 A MX2015012274 A MX 2015012274A MX 2015012274 A MX2015012274 A MX 2015012274A MX 2015012274 A MX2015012274 A MX 2015012274A MX 2015012274 A MX2015012274 A MX 2015012274A
Authority
MX
Mexico
Prior art keywords
androgen receptor
regulating agents
receptor down
compounds
diseases
Prior art date
Application number
MX2015012274A
Other languages
English (en)
Inventor
Vincent C O Njar
Lalji K Gediya
Puranik Purushottamachar
Abhijit Godbole
Andrew Kwegyir-Afful
Tadas Vasaitis
Original Assignee
Univ Maryland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Maryland filed Critical Univ Maryland
Publication of MX2015012274A publication Critical patent/MX2015012274A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed

Abstract

La presente descripción proporciona el diseño y la síntesis de compuestos esteroidales novedosos que provocan la sub-regulación del receptor de andrógeno (AR), la variante tanto de longitud completa como de empalme. Los compuestos son agentes potenciales para el tratamiento de todas las formas de cáncer de próstata y otras enfermedades que dependen del AR funcional.
MX2015012274A 2013-03-14 2014-03-14 Agentes de sub-regulacion del receptor de androgeno y uso de los mismos. MX2015012274A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361782383P 2013-03-14 2013-03-14
PCT/US2014/029667 WO2014153215A1 (en) 2013-03-14 2014-03-14 Androgen receptor down-regulating agents and uses thereof

Publications (1)

Publication Number Publication Date
MX2015012274A true MX2015012274A (es) 2016-06-02

Family

ID=51583862

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015012274A MX2015012274A (es) 2013-03-14 2014-03-14 Agentes de sub-regulacion del receptor de androgeno y uso de los mismos.

Country Status (13)

Country Link
US (2) US9884067B2 (es)
EP (2) EP4066841A1 (es)
JP (1) JP2016514165A (es)
KR (1) KR20150127720A (es)
CN (1) CN105682662A (es)
AU (1) AU2014236135A1 (es)
BR (1) BR112015023098A2 (es)
CA (1) CA2904170A1 (es)
IL (1) IL240820A0 (es)
MX (1) MX2015012274A (es)
RU (1) RU2015137617A (es)
SG (1) SG11201507093WA (es)
WO (1) WO2014153215A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100047338A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
EP4066841A1 (en) 2013-03-14 2022-10-05 University of Maryland, Baltimore Androgen receptor down-regulating agents and uses thereof
EP3514147B1 (en) * 2013-04-04 2022-08-03 University of Maryland, Baltimore Steroidal compounds with potent androgen receptor down-regulation and anti prostate cancer activity
CN105636594A (zh) 2013-08-12 2016-06-01 托凯药业股份有限公司 使用雄激素靶向疗法用于治疗肿瘤性疾病的生物标记物
US10675289B2 (en) 2014-10-02 2020-06-09 University Of Maryland, Baltimore Methods of treating pancreatic cancer
CN105713063A (zh) * 2014-12-02 2016-06-29 重庆安格龙翔医药科技有限公司 一种阿比特龙乙酸酯的制备方法
US10682362B2 (en) 2015-10-14 2020-06-16 Wayne State University Treatments and diagnostics for cancers
WO2017140183A1 (zh) * 2016-02-19 2017-08-24 深圳市塔吉瑞生物医药有限公司 一种取代的甾体类化合物及其应用
CN107365343A (zh) * 2016-05-12 2017-11-21 四川海思科制药有限公司 一种苯并咪唑雄甾衍生物及其制备方法和医药用途
US20190169227A1 (en) * 2016-06-22 2019-06-06 University Of Maryland, Baltimore Method for production of novel galeterone analogs and uses thereof
WO2019023651A2 (en) 2017-07-28 2019-01-31 Massachusetts Institute Of Technology MODULATORS OF THE SMALL MOLECULE ANDROGEN RECEPTOR
CN107857790A (zh) * 2017-12-14 2018-03-30 中国药科大学 一种新型甾体类雄激素受体抑制剂、制备方法及其医药用途
CN116444599A (zh) * 2022-01-07 2023-07-18 中国科学院上海药物研究所 甾体类化合物及制备方法和用途

Family Cites Families (228)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2664423A (en) 1952-03-12 1953-12-29 Searle & Co 4-(cyclopentanopolyhydrophenanthr-17-yl) imidazoles and derivatives thereof
GB972672A (en) 1960-01-14 1964-10-14 Ciba Ltd Pharmaceutical preparations containing compounds of the androstane series
US3060174A (en) 1960-01-14 1962-10-23 Ciba Geigy Corp Esters of the androstane series and process for their manufacture
US3317520A (en) 1965-03-05 1967-05-02 Sterling Drug Inc Steroido[20, 21-c]pyrazoles and intermediates
US3313809A (en) 1965-03-05 1967-04-11 Sterling Drug Inc Steroido[21, 20-d]isoxazoles
DE1493169A1 (de) 1965-09-03 1969-06-04 Schering Ag Verfahren zur Herstellung von 5 beta-Bisnorcholanderivaten
US3480621A (en) 1967-01-17 1969-11-25 Phytogen Prod Inc Steroid ketal
CH621803A5 (es) 1974-08-08 1981-02-27 Siphar Sa
JPS563000Y2 (es) 1976-07-27 1981-01-23
JPS563000A (en) 1979-06-20 1981-01-13 Green Cross Corp:The Water-soluble cholesterol derivative
US4316885A (en) 1980-08-25 1982-02-23 Ayerst, Mckenna And Harrison, Inc. Acyl derivatives of rapamycin
US4469689A (en) 1983-03-30 1984-09-04 The Upjohn Company Sulfonate containing ester prodrugs of corticosteroids
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4650803A (en) 1985-12-06 1987-03-17 University Of Kansas Prodrugs of rapamycin
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US5232917A (en) 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5843708A (en) 1988-01-05 1998-12-01 Ciba-Geigy Corporation Chimeric antibodies
IT1216687B (it) 1988-04-01 1990-03-08 Boehringer Biochemia Srl Complessi di platino (ii), loro preparazione e impiego come antitumorali.
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US5028726A (en) 1990-02-07 1991-07-02 The University Of Vermont And State Agricultural College Platinum amine sulfoxide complexes
US5264428A (en) 1990-02-16 1993-11-23 Kanoldt Arzneimittel Gmbh Use of stigmasta-4-en-3-one in the treatment of androgen dependent diseases
US5637459A (en) 1990-06-11 1997-06-10 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chimeric selex
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5567588A (en) 1990-06-11 1996-10-22 University Research Corporation Systematic evolution of ligands by exponential enrichment: Solution SELEX
US5683867A (en) 1990-06-11 1997-11-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: blended SELEX
DE69128350T2 (de) 1990-06-11 1998-03-26 Nexstar Pharmaceuticals Inc Nukleinsäureliganden
US5496938A (en) 1990-06-11 1996-03-05 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to HIV-RT and HIV-1 rev
US6011020A (en) 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US5707796A (en) 1990-06-11 1998-01-13 Nexstar Pharmaceuticals, Inc. Method for selecting nucleic acids on the basis of structure
US5660985A (en) 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
US5300294A (en) 1990-06-27 1994-04-05 Smithkline Beecham Corporation Method of treating prostatic adenocarcinoma
US5385936A (en) 1990-07-12 1995-01-31 The United States Of America As Represented By The Secretary Of The Department Of The Health And Human Services Gossypol acetic acid for the treatment of cancer
US5023264A (en) 1990-07-16 1991-06-11 American Home Products Corporation Rapamycin oximes
AU637247B2 (en) 1990-08-01 1993-05-20 Merrell Dow Pharmaceuticals Inc. 4-amino-delta4-steroids and their use as 5alpha-reductase inhibitors
US5023263A (en) 1990-08-09 1991-06-11 American Home Products Corporation 42-oxorapamycin
US5612205A (en) 1990-08-29 1997-03-18 Genpharm International, Incorporated Homologous recombination in mammalian cells
PT98990A (pt) 1990-09-19 1992-08-31 American Home Prod Processo para a preparacao de esteres de acidos carboxilicos de rapamicina
US5221670A (en) 1990-09-19 1993-06-22 American Home Products Corporation Rapamycin esters
US5233036A (en) 1990-10-16 1993-08-03 American Home Products Corporation Rapamycin alkoxyesters
US5120842A (en) 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
US5100883A (en) 1991-04-08 1992-03-31 American Home Products Corporation Fluorinated esters of rapamycin
KR0182801B1 (ko) 1991-04-16 1999-05-01 아만 히데아키 고체 분산체의 제조방법
US5118678A (en) 1991-04-17 1992-06-02 American Home Products Corporation Carbamates of rapamycin
US5118677A (en) 1991-05-20 1992-06-02 American Home Products Corporation Amide esters of rapamycin
US5162333A (en) 1991-09-11 1992-11-10 American Home Products Corporation Aminodiesters of rapamycin
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5151413A (en) 1991-11-06 1992-09-29 American Home Products Corporation Rapamycin acetals as immunosuppressant and antifungal agents
GB9125660D0 (en) 1991-12-03 1992-01-29 Smithkline Beecham Plc Novel compound
US5264427A (en) 1992-01-29 1993-11-23 Research Corporation Technologies, Inc. 20-substituted pregnene derivatives and their use as androgen synthesis inhibitors
US5177203A (en) 1992-03-05 1993-01-05 American Home Products Corporation Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents
ES2138618T3 (es) 1992-03-31 2000-01-16 Btg Int Ltd Esteroides 17-sustituidos utiles en el tratamiento del cancer.
US5604213A (en) 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
US5620986A (en) 1992-05-20 1997-04-15 Merck & Co., Inc. 17 urea, thiourea, thiocarbamyl and carbamyl4-azasteroid 5-reductase inhibitors useful in the prevention and treatment of hyperandrogenic disorders
US5237064A (en) 1992-05-20 1993-08-17 Merck & Co., Inc. Process for producing 7β-substituted-aza-5αandrostan-3-ones
ZA935112B (en) 1992-07-17 1994-02-08 Smithkline Beecham Corp Rapamycin derivatives
ZA935111B (en) 1992-07-17 1994-02-04 Smithkline Beecham Corp Rapamycin derivatives
US5256790A (en) 1992-08-13 1993-10-26 American Home Products Corporation 27-hydroxyrapamycin and derivatives thereof
US6042828A (en) 1992-09-07 2000-03-28 Kyowa Hakko Kogyo Co., Ltd. Humanized antibodies to ganglioside GM2
DE4232681C2 (de) 1992-09-29 1994-11-24 Sigma Tau Ind Farmaceuti 17-Phenyl- und 17-Furyl-14beta,5alpha-androstan- und androsten- Derivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzung
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5434260A (en) 1992-10-13 1995-07-18 American Home Products Corporation Carbamates of rapamycin
US5302584A (en) 1992-10-13 1994-04-12 American Home Products Corporation Carbamates of rapamycin
US5411967A (en) 1992-10-13 1995-05-02 American Home Products Corporation Carbamates of rapamycin
US5480989A (en) 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5489680A (en) 1992-10-13 1996-02-06 American Home Products Corporation Carbamates of rapamycin
US5480988A (en) 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5262423A (en) 1992-10-29 1993-11-16 American Home Products Corporation Rapamycin arylcarbonyl and alkoxycarbonyl carbamates as immunosuppressive and antifungal agents
US5258389A (en) 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
US5260300A (en) 1992-11-19 1993-11-09 American Home Products Corporation Rapamycin carbonate esters as immuno-suppressant agents
US5504091A (en) 1993-04-23 1996-04-02 American Home Products Corporation Biotin esters of rapamycin
CA2161531A1 (en) 1993-04-30 1994-11-10 Donald C. Malins Dna profiles as an indicator of cellular redox potential and cancer risk
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US5837832A (en) 1993-06-25 1998-11-17 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
US5858659A (en) 1995-11-29 1999-01-12 Affymetrix, Inc. Polymorphism detection
US5378836A (en) 1993-10-08 1995-01-03 American Home Products Corporation Rapamycin oximes and hydrazones
US5391730A (en) 1993-10-08 1995-02-21 American Home Products Corporation Phosphorylcarbamates of rapamycin and oxime derivatives thereof
US5373014A (en) 1993-10-08 1994-12-13 American Home Products Corporation Rapamycin oximes
CA2175215C (en) 1993-11-19 2008-06-03 Yat Sun Or Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
US5385909A (en) 1993-11-22 1995-01-31 American Home Products Corporation Heterocyclic esters of rapamycin
US5385908A (en) 1993-11-22 1995-01-31 American Home Products Corporation Hindered esters of rapamycin
US5385910A (en) 1993-11-22 1995-01-31 American Home Products Corporation Gem-distributed esters of rapamycin
SK78196A3 (en) 1993-12-17 1997-02-05 Sandoz Ag Rapamycin demethoxy-derivatives, preparation method thereof and pharmaceutical agent containing them
US5637310A (en) 1993-12-20 1997-06-10 Smithkline Beecham Corporation Method of treating prostatic adenocarcinoma
US5389639A (en) 1993-12-29 1995-02-14 American Home Products Company Amino alkanoic esters of rapamycin
US5578832A (en) 1994-09-02 1996-11-26 Affymetrix, Inc. Method and apparatus for imaging a sample on a device
US5631734A (en) 1994-02-10 1997-05-20 Affymetrix, Inc. Method and apparatus for detection of fluorescently labeled materials
TW385308B (en) 1994-03-04 2000-03-21 Merck & Co Inc Prodrugs of morpholine tachykinin receptor antagonists
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5571639A (en) 1994-05-24 1996-11-05 Affymax Technologies N.V. Computer-aided engineering system for design of sequence arrays and lithographic masks
US5463048A (en) 1994-06-14 1995-10-31 American Home Products Corporation Rapamycin amidino carbamates
US6974666B1 (en) 1994-10-21 2005-12-13 Appymetric, Inc. Methods of enzymatic discrimination enhancement and surface-bound double-stranded DNA
WO1997027317A1 (en) 1996-01-23 1997-07-31 Affymetrix, Inc. Nucleic acid analysis techniques
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
US5491231A (en) 1994-11-28 1996-02-13 American Home Products Corporation Hindered N-oxide esters of rapamycin
US5563145A (en) 1994-12-07 1996-10-08 American Home Products Corporation Rapamycin 42-oximes and hydroxylamines
US5599695A (en) 1995-02-27 1997-02-04 Affymetrix, Inc. Printing molecular library arrays using deprotection agents solely in the vapor phase
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6410690B1 (en) 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
US6113898A (en) 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
ES2187660T3 (es) 1995-06-09 2003-06-16 Novartis Ag Derivados de rapamicina.
US5856174A (en) 1995-06-29 1999-01-05 Affymetrix, Inc. Integrated nucleic acid diagnostic device
EP0862436A1 (en) 1995-10-19 1998-09-09 Merck & Co., Inc. 16-substituted-6-aza-steroid 5-alpha-reductase inhibitors
US5780462A (en) 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
US6228575B1 (en) 1996-02-08 2001-05-08 Affymetrix, Inc. Chip-based species identification and phenotypic characterization of microorganisms
US6458530B1 (en) 1996-04-04 2002-10-01 Affymetrix Inc. Selecting tag nucleic acids
WO1998002441A2 (en) 1996-07-12 1998-01-22 Ariad Pharmaceuticals, Inc. Non immunosuppressive antifungal rapalogs
US6368598B1 (en) 1996-09-16 2002-04-09 Jcrt Radiation Oncology Support Services, Inc. Drug complex for treatment of metastatic prostate cancer
US5994334A (en) 1997-02-05 1999-11-30 University Of Maryland Androgen synthesis inhibitors
ES2287971T3 (es) 1997-08-11 2007-12-16 Pfizer Products Inc. Dispersiones farmaceuticas solidas con biodisponibilidad incrementada.
US5994335A (en) 1997-10-17 1999-11-30 The University Of Maryland, Baltimore 17-azolyl steroids useful as androgen synthesis inhibitors
US20030059471A1 (en) 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
KR100525275B1 (ko) 1998-04-10 2005-11-02 미쓰비시 가가꾸 가부시키가이샤 시알산 유도체를 함유하는 고체분산체
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
EP1027885B1 (en) 1999-02-09 2008-07-09 Pfizer Products Inc. Basic drug compositions with enhanced bioavailability
ES2219388T3 (es) 1999-08-24 2004-12-01 Ariad Gene Therapeutics, Inc. 28-epi-rapalogos.
JP4803933B2 (ja) 1999-08-27 2011-10-26 ブリストル−マイヤーズ スクウィブ カンパニー インビトロ翻訳タンパク質の符号化方法および選別方法
DE60037455T2 (de) 1999-09-17 2008-11-27 Abbott Gmbh & Co. Kg Kinaseinhibitoren als arzneimittel
CA2386095A1 (en) 1999-09-30 2001-04-05 Hollis-Eden Pharmaceuticals, Inc. Therapeutic treatment of androgen receptor driven conditions
EE200200357A (et) 1999-12-23 2003-10-15 Pfizer Products Inc. Ravimaine suurenenud kontsentratsioone andvad farmatseutilised kompositsioonid
MY138883A (en) 2000-08-29 2009-08-28 Government Of Malaysia As Represented By The Ministry Of Science Tehnology And Innovation Malaysia Use of asiatic acid for treatment of cencer
US20020165381A1 (en) 2000-11-30 2002-11-07 Isabelle Ahrens-Fath Human androgen receptor variants
UA80393C2 (uk) 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
WO2002083139A1 (en) 2001-04-10 2002-10-24 Merck & Co., Inc. Inhibitors of akt activity
AU2002251266A1 (en) 2001-04-10 2002-10-28 Merck Sharp And Dohme Limited Inhibitors of akt activity
EP1269994A3 (en) 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
US20030054053A1 (en) 2001-09-20 2003-03-20 Charles Young Methods and compositions for inhibiting the proliferation of prostate cancer cells
DK1436257T3 (da) 2001-10-12 2007-06-25 Univ Johns Hopkins Oxim-analogica af 1-alpha, 25-dihydroxy-vitamin-D3 med ringe kalcemisk virkning
SE0103424D0 (sv) 2001-10-15 2001-10-15 Astrazeneca Ab Pharmaceutical formulation
US20070015713A1 (en) 2005-07-14 2007-01-18 Voyager Pharmaceutical Corporation Methods for treating prostate cancer
RU2288703C2 (ru) 2002-02-01 2006-12-10 Пфайзер Продактс Инк. Способ создания однородных высушенных распылением твердых аморфных лекарственных дисперсных систем с использованием распыляющих напорных форсунок (варианты) и продукт
RS61604A (en) 2002-02-01 2006-10-27 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
US7223738B2 (en) 2002-04-08 2007-05-29 Merck & Co., Inc. Inhibitors of Akt activity
JP4451136B2 (ja) 2002-04-08 2010-04-14 メルク エンド カムパニー インコーポレーテッド Ａｋｔ活性阻害薬
EP1530457B1 (en) 2002-08-12 2009-09-09 Bend Research, Inc. Pharmaceutical compositions of drugs in semi-ordered form and polymers
EP1537129B1 (en) 2002-09-03 2013-11-06 Georgetown University Akt inhibitors, pharmaceutical compositions, and uses thereof
US6933312B2 (en) 2002-10-07 2005-08-23 Agouron Pharmaceuticals, Inc. Pyrazole derivatives
JP2006507299A (ja) 2002-10-30 2006-03-02 メルク　エンド　カムパニー　インコーポレーテッド Ａｋｔ活性の阻害薬
TW200500360A (en) 2003-03-01 2005-01-01 Astrazeneca Ab Hydroxymethyl compounds
JP4616831B2 (ja) 2003-04-24 2011-01-19 メルク・シャープ・エンド・ドーム・コーポレイション Ａｋｔ活性の阻害剤
ATE446752T1 (de) 2003-04-24 2009-11-15 Merck & Co Inc Hemmer der akt aktivität
WO2004096129A2 (en) 2003-04-24 2004-11-11 Merck & Co., Inc. Inhibitors of akt activity
JP2006524254A (ja) 2003-04-24 2006-10-26 メルク　エンド　カムパニー　インコーポレーテッド Ａｋｔ活性の阻害剤
US7439268B2 (en) 2003-07-18 2008-10-21 Idexx Laboratories Compositions containing prodrugs of florfenicol and methods of use
RU2351357C2 (ru) 2003-07-29 2009-04-10 ДОМПЕ ФА.Р.МА. С.п.А. Фармацевтическая композиция, используемая для мобилизации стволовых клеток
EP1656129A4 (en) 2003-08-22 2009-03-11 Univ Virginia MTOR BLOCUS FOR PREVENTING HORMONE ADAPTIVE RESPONSE
US7605120B2 (en) 2003-10-22 2009-10-20 Amgen Inc. Antagonists of the brandykinin B1 receptor
JP2007511596A (ja) 2003-11-17 2007-05-10 ファイザー・プロダクツ・インク 癌の治療において有用なピロロピリミジン化合物
JP4585201B2 (ja) 2004-01-23 2010-11-24 丸善製薬株式会社 アンドロゲン受容体結合阻害剤、養毛剤、皮脂分泌抑制剤及び前立腺肥大抑制剤
US20070185152A1 (en) 2004-03-02 2007-08-09 Smithkline Beecham Corporation Inhibitors of akt activity
JP2007530582A (ja) 2004-03-26 2007-11-01 ライジェル ファーマシューティカルズ， インコーポレイテッド 代謝可能部分を含む複素環抗ウイルス化合物およびその使用
WO2005098446A2 (en) 2004-03-31 2005-10-20 The Johns Hopkins University Biomarkers for ovarian cancer
EA013209B1 (ru) 2004-04-08 2010-04-30 Топотаргет А/С Производные дифенилоксиндол-2-она и их применение для лечения рака
WO2005100356A1 (en) 2004-04-09 2005-10-27 Merck & Co., Inc. Inhibitors of akt activity
AU2005233584B2 (en) 2004-04-09 2010-12-09 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
US7604947B2 (en) 2004-06-09 2009-10-20 Cornell Research Foundation, Inc. Detection and modulation of cancer stem cells
US20060013873A1 (en) 2004-07-16 2006-01-19 Chih-Chiang Yang Bioadhesive dosage form of steroids
WO2006036395A2 (en) 2004-08-23 2006-04-06 Merck & Co., Inc. Inhibitors of akt activity
CN101133036B (zh) * 2004-09-30 2010-10-13 詹森药业有限公司 可用作选择性雄激素受体调节剂(sarms)的新苯并咪唑衍生物
CN101115479A (zh) 2005-02-14 2008-01-30 默克公司 Akt活性抑制剂
US20100047338A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
NZ561571A (en) 2005-03-02 2009-09-25 Univ Maryland Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity
WO2006099121A2 (en) 2005-03-10 2006-09-21 Elan Pharma International Limited Formulations of a nanoparticulate finasteride, dutasteride and tamsulosin hydrochloride, and mixtures thereof
DE102005011786A1 (de) 2005-03-11 2006-09-14 Pharmasol Gmbh Verfahren zur Herstellung ultrafeiner Submicron-Suspensionen
AU2006235314B2 (en) 2005-04-12 2011-01-20 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
MX2007015578A (es) 2005-06-10 2008-03-06 Merck & Co Inc Inhibidores de la actividad akt.
US8440409B2 (en) 2005-09-19 2013-05-14 The Johns Hopkins University Protein C inhibitor as a biomarker for prostate cancer
ES2436877T3 (es) 2005-11-17 2014-01-07 OSI Pharmaceuticals, LLC Intermedios para la preparación de inhibidores de mTOR bicíclicos condensados
AR057960A1 (es) 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
WO2007087395A2 (en) 2006-01-25 2007-08-02 Osi Pharmaceuticals, Inc. UNSATURATED mTOR INHIBITORS
US7943732B2 (en) 2006-06-05 2011-05-17 Intrexon Corporation AKT ligands and polynucleotides encoding AKT ligands
BRPI0713555A2 (pt) 2006-07-06 2012-03-20 Array Biopharma, Inc. ciclopenta [d] pirimidinas como inibidores de akt protéina cinase
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
EP2059595A2 (en) 2006-08-30 2009-05-20 Novartis AG Compositions and methods for modulating mtor signaling
CA2700573C (en) 2006-09-26 2016-11-22 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
WO2008047201A2 (en) 2006-10-17 2008-04-24 Pfizer Products Inc. Solid dispersion comprising a poorly water soluble drug
AR064010A1 (es) 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt
WO2008070823A2 (en) 2006-12-07 2008-06-12 University Of South Florida Substrate-mimetic akt inhibitor
WO2008076918A2 (en) 2006-12-15 2008-06-26 University Of Maryland, Baltimore Anti-cancer agents and androgen inhibition activity compound
US7807393B2 (en) 2007-01-29 2010-10-05 Northwestern University Biomarkers for prostate cancer
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
SI2131821T1 (sl) 2007-03-07 2018-11-30 Abraxis Bioscience, Llc Nanodelci, ki zajemajo rapamicin in albumin kot sredstvo proti raku
WO2008154382A1 (en) 2007-06-06 2008-12-18 University Of Maryland, Baltimore Hdac inhibitors and hormone targeted drugs for the treatment of cancer
EP2359828A1 (en) 2007-06-06 2011-08-24 University of Maryland, Baltimore HDAC inhibitors and hormone targeted drugs for the treatment of cancer
US20090012045A1 (en) 2007-06-26 2009-01-08 Rigel Pharmaceuticals, Inc. Methods of Treating Cell Proliferative Disorders
US20090047252A1 (en) 2007-06-29 2009-02-19 Gilead Sciences, Inc. Antiviral compounds
CL2009000035A1 (es) 2008-01-09 2009-11-27 Array Biopharma Inc Compuestos derivados 3-espiro-heterociclo-1il-5h-ciclopentan[d]pirimidin-indol, util para inhibir la actividad de akt quinasa; composicion farmaceutica que comprende dichos compuestos; y uso en el tratamiento de enfermedades tal como cancer, fibrosis quistica, diabetes, enfermedad de alzheimer, entre otras.
GB2470873A (en) 2008-03-12 2010-12-08 Univ Maryland Androgen receptor inactivation contributes to antitumor efficacy of CYP17 inhibitors in prostrate cancer
US20110118219A1 (en) 2008-03-25 2011-05-19 University Of Maryland, Baltimore Novel prodrugs of c-17-heteroaryl steroidal cyp17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity
WO2009129208A2 (en) 2008-04-14 2009-10-22 University Of Maryland, Baltimore Compositions and methods of inducing endoplasmic reticulum stress reponse
ES2836128T3 (es) 2008-04-16 2021-06-24 Univ Johns Hopkins Método para determinar variantes del receptor de andrógenos en cáncer de próstata
WO2010008847A2 (en) 2008-06-24 2010-01-21 Takeda Pharmaceutical Company Limited Pi3k/m tor inhibitors
WO2010089763A2 (en) 2008-06-30 2010-08-12 Reliance Life Sciences Pvt. Ltd. Poly(n-vinyl caprolactam-co-acrylamide) microparticles for controlled release applications
WO2010006072A2 (en) 2008-07-08 2010-01-14 The Regents Of The University Of California Mtor modulators and uses thereof
WO2010011893A1 (en) 2008-07-24 2010-01-28 University Of Central Florida Research Foundation, Inc. Therapy targeting cancer stem cells
CA2735716A1 (en) 2008-09-12 2010-03-18 Dako Denmark A/S Prostate cancer biomarker
US8841422B2 (en) 2008-09-17 2014-09-23 University Of Maryland, Baltimore Human androgen receptor alternative splice variants
US8133724B2 (en) 2008-09-17 2012-03-13 University Of Maryland, Baltimore Human androgen receptor alternative splice variants as biomarkers and therapeutic targets
RU2538683C2 (ru) 2008-10-31 2015-01-10 Новартис Аг КОМБИНАЦИЯ ИНГИБИТОРА ФОСФАТИДИЛИНОЗИТОЛ-3-КИНАЗЫ (Р13К) И ИНГИБИТОРА mTOR
CN101607985B (zh) 2008-12-24 2013-03-27 中国科学院生物物理研究所 抗人cea的单克隆抗体，包含其的组合物，及其用途
US8791095B2 (en) 2009-02-05 2014-07-29 Tokai Pharmaceuticals, Inc. Steroidal CYP17 inhibitors/antiandrogens
US20110312916A1 (en) 2009-02-05 2011-12-22 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
US20110319369A1 (en) 2009-02-05 2011-12-29 Tokai Pharmaceuticals, Inc. Combination of a 17 alpha-hydroxylase/c17, 20-lyase inhibitor with an additional therapeutic agent
US8168652B2 (en) 2009-03-12 2012-05-01 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
PT3130396T (pt) 2009-03-27 2021-05-12 Bend Res Inc Processo de secagem por pulverização
AU2010279398A1 (en) 2009-08-07 2012-03-08 Tokai Pharmaceuticals, Inc. Treatment of prostate cancer
US20120282331A1 (en) 2009-11-13 2012-11-08 Tokai Pharmaceuticals, Inc. Mammalian metabolites of steroids
CA2791244A1 (en) 2010-03-08 2011-09-15 Regents Of The University Of Minnesota Androgen receptor isoforms and methods
US8703712B2 (en) 2010-03-18 2014-04-22 The Uab Research Foundation Targeting cancer stem cells with DR5 agonists
WO2012006241A2 (en) 2010-07-06 2012-01-12 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of androgen receptor by double-stranded rna
US20120028972A1 (en) 2010-07-30 2012-02-02 Lilly Wong Biomarker assays for detecting or measuring inhibition of tor kinase activity
RU2013132766A (ru) 2010-12-16 2015-01-27 Байомарин Фармасьютикал Инк. Ингибиторы cyp11b, cyp17 и/или cyp21
US8946409B2 (en) 2011-01-27 2015-02-03 Board Of Regents, The University Of Texas System Polycyclic β lactam derivatives for the treatment of cancer
WO2012129408A2 (en) 2011-03-22 2012-09-27 The Johns Hopkins University Biomarkers for aggressive prostate cancer
CN103813794A (zh) 2011-07-18 2014-05-21 拓凯制药公司 用于治疗前列腺癌的新型组合物及方法
RU2640485C2 (ru) 2011-11-30 2018-01-09 Астразенека Аб Комбинированное лечение рака
CA2859986A1 (en) 2011-12-22 2013-06-27 Tokai Pharmaceuticals, Inc. Methods and compositions for combination therapy using pi3k/mtor inhibitors
NZ704487A (en) 2012-07-27 2018-05-25 Aragon Pharmaceuticals Inc Methods and compositions for determining resistance to androgen receptor therapy
WO2014047285A1 (en) 2012-09-19 2014-03-27 Paraskevi Giannakakou Identifying taxane sensitivity in prostate cancer patients
EP4066841A1 (en) * 2013-03-14 2022-10-05 University of Maryland, Baltimore Androgen receptor down-regulating agents and uses thereof
CN105636594A (zh) * 2013-08-12 2016-06-01 托凯药业股份有限公司 使用雄激素靶向疗法用于治疗肿瘤性疾病的生物标记物
EP3186393A4 (en) 2014-08-25 2018-01-10 The Johns Hopkins University Methods and compositions related to prostate cancer therapeutics
WO2016172517A1 (en) 2015-04-24 2016-10-27 Tokai Pharmaceuticals, Inc. Methods of treating prostate cancer

Also Published As

Publication number Publication date
AU2014236135A1 (en) 2015-09-10
CA2904170A1 (en) 2014-09-25
EP2968370A1 (en) 2016-01-20
JP2016514165A (ja) 2016-05-19
RU2015137617A (ru) 2017-04-18
WO2014153215A8 (en) 2015-11-05
US20150361126A1 (en) 2015-12-17
EP2968370A4 (en) 2016-09-21
EP4066841A1 (en) 2022-10-05
WO2014153215A1 (en) 2014-09-25
KR20150127720A (ko) 2015-11-17
US9884067B2 (en) 2018-02-06
SG11201507093WA (en) 2015-10-29
CN105682662A (zh) 2016-06-15
IL240820A0 (en) 2015-10-29
US20160000808A1 (en) 2016-01-07
US9439912B2 (en) 2016-09-13
BR112015023098A2 (pt) 2017-07-18

Similar Documents

Publication Publication Date Title
MX2015012274A (es) Agentes de sub-regulacion del receptor de androgeno y uso de los mismos.
MY191169A (en) Anti-fcrh5 antibodies
MX2016001901A (es) Biomarcadores para tratamiento de trastornos neoplasicos usando terapias dirigidas con andrógeno.
EA201991772A1 (ru) Способ лечения рака предстательной железы с использованием комбинации на основе модулятора андрогенного рецептора
HK1221711A1 (zh) 前列腺特異性膜抗原 的標記的抑制劑，它們作為顯影劑和用於治療前列腺癌的藥劑的用途
TN2015000396A1 (en) Antibody drug conjugates
AU2014358850A8 (en) Estrogen receptor modulator for the treatment of locally advanced or metastatic estrogen receptor positive breast cancer
MX2016007576A (es) Anticuerpos e inmunoconjugados anti-cd33.
MX2016004570A (es) Uso de inhibidores del bromodominio de cbp/ep300 para la inmunoterapia del cáncer.
IN2014DN05885A (es)
MX2016004853A (es) Metodos de uso de anticuerpos anti-ly6e.
PH12015502342A1 (en) Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
PL3089749T3 (pl) Preparaty skojarzone do leczenia raka
HK1222869A1 (zh) 用於治療癌症的針對 的偶聯抗體
IN2014KN02993A (es)
EP3433239A4 (en) SMALL MOLECULAR INHIBITORS OF THE NUCLEAR TRANSLOCATION OF THE ANDROGEN RECEPTOR FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER
MX2015013021A (es) 5-bromo-indirrubinas.
PH12016501173A1 (en) Quinazolin-thf-amines as pde1 inhibitors
PH12016501201A1 (en) Synthesis of ent-progesterone and intermediates thereof
EP3003490A4 (en) Combination therapy for prostate cancer using botanical compositions and docetaxel
MX2016004573A (es) Inhibidores de nsp4 y metodos de uso.
MX2015012902A (es) Sintesis de ent-progesterona e intermediarios de la misma.
MX2015010789A (es) Anticuerpos anti-pcsm.
PH12018500508A1 (en) Methods for the synthesis of spingomyelins and dihydrosphingomyelins
IN2013DE02958A (es)